However, an ENU-based genetic screen for abnormal CNS axonal tracks identified a viable B4gat1(B3gnt1) dystroglycanopathy mouse model carrying a p.M155T B4gat1 mutation (Wright et al., 2012). The gene discussed is B4GAT1; the disease is neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.